PMID: 7540965Jun 1, 1995Paper

Design of the Prostate Cancer Prevention Trial (PCPT)

Controlled Clinical Trials
P FeiglL G Ford

Abstract

The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsy-proven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) and half will receive placebo (one matching tablet per day) for 7 years. The trial is designed to have 92% power to detect a 25% reduction in period prevalence of biopsy-proven disease using a two-sided test with alpha = 0.05. The trial is complicated by the known impact of finasteride on the major screening test for prostate cancer, prostate specific antigen (PSA). This paper describes the PCPT design with reference to alternatives that were considered. The chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.

References

Oct 22, 1992·The New England Journal of Medicine·G J GormleyJ S Tenover
Oct 7, 1992·Journal of the National Cancer Institute·T Reynolds
Apr 25, 1991·The New England Journal of Medicine·W J CatalonaG L Andriole
Feb 25, 1991·Cancer·W F WhitmoreI M Thompson
Jan 1, 1990·Statistics in Medicine·J Wittes, E Brittain
Jan 1, 1980·Scandinavian Journal of Urology and Nephrology·B Hølund
Oct 1, 1984·Statistics in Medicine·S YusufR Peto
Jan 27, 1994·The New England Journal of Medicine·G W ChodakJ Warner
Aug 1, 1993·Controlled Clinical Trials·M D ThornquistM Cherniack

❮ Previous
Next ❯

Citations

Mar 29, 2001·Journal of Surgical Oncology·P M SimpsonJ S Spratt
Apr 11, 2001·Urology·D L TrumpB L Neubauer
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O W Brawley, H Parnes
Apr 1, 1997·Critical Reviews in Oncology/hematology·T Tanaka
Apr 10, 2003·Urologic Oncology·Otis W Brawley
Aug 1, 1997·Current Opinion in Chemical Biology·G S Harris, J W Kozarich
Nov 3, 2005·Nature Clinical Practice. Oncology·Edith D Canby-Hagino, Ian M Thompson
Jun 10, 2006·Nature Clinical Practice. Urology·Ian M Thompson, Catherine M Tangen
Mar 27, 2007·Nature Reviews. Cancer·Angelo M De MarzoWilliam G Nelson
Apr 26, 2000·BJU International·J M Fitzpatrick
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
May 21, 1997·Journal of the National Cancer Institute·J W AquilinaD G Bostwick
Nov 2, 2005·The Cancer Journal·Srinivasan VijayakumarRajendra G Mehta
Mar 17, 2004·Controlled Clinical Trials·Phyllis J GoodmanIan M Thompson
Feb 17, 2010·Clinical Trials : Journal of the Society for Clinical Trials·Elise D CookLori M Minasian
Jan 1, 1997·Journal of Cellular Biochemistry. Supplement·K A JohnsonR DeLap
Sep 26, 2008·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·J Irani
Oct 21, 2004·Cancer·David G BostwickBarry Timms
Nov 18, 2003·BJU International·M MarbergerP Teillac
May 16, 2006·The Journal of Urology·Phyllis J GoodmanCharles A Coltman
Aug 3, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Kilian Mellon
Apr 18, 2003·BJU International·J M Fitzpatrick
Apr 26, 2006·Expert Opinion on Pharmacotherapy·Edith D Canby-HaginoIan M Thompson
May 27, 2011·Acta Oncologica·Roger S Rittmaster
Jul 5, 2005·Surgical Oncology·S R J BottM Williamson
Jan 11, 2018·Molecular Carcinogenesis·Lisa W ChuAnn W Hsing

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Cellular Biochemistry. Supplement
G J KelloffG G Knapp
Prostate Cancer and Prostatic Diseases
G J KelloffG J Kelloff
© 2021 Meta ULC. All rights reserved